Cytomegalovirus Infection and Disease

Cytomegalovirus (CMV) is the single most important viral pathogen in solid-organ transplantation. A ubiquitous herpesvirus that establishes lifelong latency, it reactivates or is newly acquired under immunosuppression and can cause a spectrum ranging from asymptomatic viral replication to tissue-invasive organ disease, while also exerting indirect effects on graft and patient outcomes.

Definition

Cytomegalovirus infection denotes evidence of CMV replication (for example detectable viral DNA in blood) regardless of symptoms, whereas CMV disease denotes infection accompanied by attributable signs and symptoms, classified either as a viral syndrome (fever, malaise, cytopenias) or as tissue-invasive end-organ disease such as gastrointestinal disease, pneumonitis, or hepatitis.

Scope

This topic distinguishes CMV infection from CMV disease, outlines the central role of donor and recipient serostatus in risk, summarizes the direct and indirect effects attributed to the virus, and introduces the standardized definitions and the two principal prevention paradigms. It is reference-educational and does not specify drugs, doses, or individualized management.

Core questions

• How is CMV infection distinguished from CMV disease, and why does the distinction matter?
• Why does donor/recipient (D/R) serostatus define the risk strata for CMV after transplantation?
• What are the 'indirect' effects of CMV beyond directly attributable organ disease?
• How do the prophylaxis and pre-emptive prevention strategies differ in concept?

Key concepts

• CMV infection versus CMV disease
• Donor/recipient serostatus risk strata (D+/R- highest)
• Latency and reactivation of a herpesvirus
• Direct effects: viral syndrome and tissue-invasive disease
• Indirect effects on the allograft and immune system
• Universal prophylaxis versus pre-emptive therapy
• Quantitative nucleic-acid testing (viral load monitoring)

Mechanisms

CMV is a betaherpesvirus that, once acquired, persists latently and can reactivate when T-cell control is reduced by immunosuppression; a CMV-seronegative recipient of an organ from a seropositive donor (D+/R-) faces the highest risk because they lack pre-existing immunity to a virus carried in the graft. The virus produces direct effects by replicating and invading tissue, and standardized international definitions separate CMV infection (replication alone) from CMV disease (a viral syndrome or end-organ disease) to allow consistent assessment. CMV is also linked to indirect effects, including modulation of the immune system and associations with allograft injury and other opportunistic infections. Prevention rests on two concepts described in consensus guidelines: universal prophylaxis, in which at-risk recipients receive antiviral drugs for a defined period, and pre-emptive therapy, in which recipients are monitored by quantitative viral-load testing and treated only when replication crosses a threshold.

Clinical relevance

Because of its frequency and its direct and indirect harms, CMV is a focus of post-transplant surveillance and prevention, and standardized definitions allow programs and trials to compare outcomes consistently. This entry explains the concepts of CMV infection, disease, risk stratification, and prevention paradigms for orientation only; it does not provide antiviral regimens or individualized management advice.

Epidemiology

Risk is stratified chiefly by donor and recipient CMV serostatus, with D+/R- recipients at greatest risk and D-/R- at lowest. Without prevention, CMV typically presents in the intermediate post-transplant period, consistent with the general post-transplant infection timeline; prophylaxis can shift symptomatic disease to a later, post-prophylaxis (late-onset) period. Specific incidence varies by organ, regimen, and prevention strategy as discussed in the consensus guidelines.

History

CMV was recognized early as the most consequential infection in transplantation, and management evolved from reactive treatment toward structured prevention as effective oral antivirals and sensitive quantitative assays became available. International consensus groups subsequently standardized definitions of CMV infection and disease for clinical trials and issued successive guidelines that codified the prophylaxis and pre-emptive strategies, with the third International Consensus Guidelines representing a widely cited synthesis.

Debates

Universal prophylaxis versus pre-emptive therapy

Both strategies are endorsed for preventing CMV disease, but they differ in trade-offs — prophylaxis is simpler but is associated with late-onset disease after it stops, while pre-emptive therapy avoids unnecessary drug exposure but depends on reliable, frequent viral-load monitoring. The choice remains context-dependent in the guidelines.

Key figures

• Camille N. Kotton
• Per Ljungman
• Jay A. Fishman

Seminal works

• kotton-2018
• ljungman-2017

Frequently asked questions

What is the difference between CMV infection and CMV disease?

CMV infection means the virus is detectably replicating, often without symptoms, whereas CMV disease means that replication is accompanied by attributable illness — either a viral syndrome or tissue-invasive organ disease. International definitions formalize this distinction.

Why is a CMV-negative recipient of a CMV-positive organ at the highest risk?

Such a recipient (D+/R-) has no prior immunity to CMV but receives an organ that can carry the latent virus, so they are most likely to develop primary infection and disease after transplantation.